I don’t usually share information about so-called cancer ‘cures’, but the possibility that surgery, and even fine needle biopsies, could prompt cancer spread has interested me for many years. So when I came across this blog and understood the scientific reasoning behind the hope, I felt it could be important.
The story is explained on a blog by Ralph W Moss PhD, 28 December 2018:
“About ten years ago, an anesthesiologist named Patrice Forget, MD, PhD (pronounced “For-shay”), of University Hospital, Brussels, compared the cancer recurrence rate of 327 women. All the women had received one of four different painkillers during their surgery for breast cancer. Dr. Forget found something astonishing. There was a greatly reduced risk of a distant relapse among breast cancer patients who got ketorolac. This was compared to patients who received the three other non-NSAID painkillers. They got no such benefit.
There was a good scientific reason why this would be so. As the name implies, an NSAID is an anti-inflammatory drug, not specifically a breast cancer pill. And as Dr. Forget has said: “Surgery and inflammation are closely associated, and linked to mechanisms that promote tumor growth.”
…When a surgeon removes a tumor, the resulting surgical wound causes systemic inflammation for a week or so. The body, in trying to heal that wound, release some hormone-like compounds to speed healing. But these growth and repair signals can have an unanticipated side effect. If the patients have any remaining cancer cells in their bodies, the normal wound healing can stimulate the re-growth of their cancers.”
The blog goes on to explain how the pill works by reducing systemic inflammation and so preventing the growth of new blood supplies to micro-metastases and stopping the growth of a new tumour.
Is it proven too work? Two retrospective studies have shown and a 41% and 45% reduction in the risk of distant recurrences. “These two studies show “a definite benefit of perioperative ketorolac in breast cancer,” according to Dr. Michael Retsky of the Harvard School of Public Health.
The ideas have been put forward in a medical textbook by Michael W Retsky and Romano Demicheli: Perioperative Inflammation as Triggering Origin of Metastases Development, Springer.
Please note – further clinical trials are needed before any definite benefit of ketolac as an anti-cancer drug can be proven.